Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.


Journal Article (Review)

Women are underrepresented in cardiovascular studies, even as their preponderance in the aging population steadily increases. Although concerns have been raised about the differential benefit of antiplatelet medications for women, the propensity for increased bleeding among women has also been recognized. A better understanding of the factors contributing to the observed sex-related differences in platelet biology is warranted. These factors include differences in the frequency and expression of genetic polymorphisms affecting platelet responsiveness to agonists (with and without antiplatelet therapies), which might be obtained through population-based studies and in large controlled clinical trials; inflammatory marker levels and their influence on atherothrombotic risk, and the role of specific hormones in mediating platelet activation and function. Knowledge gained about these mechanistic factors might inform the development of sex-specific antithrombotic treatment regimens that confer optimized safety and efficacy.

Full Text

Duke Authors

Cited Authors

  • Wang, TY; Angiolillo, DJ; Cushman, M; Sabatine, MS; Bray, PF; Smyth, SS; Dauerman, HL; French, PA; Becker, RC

Published Date

  • March 6, 2012

Published In

Volume / Issue

  • 59 / 10

Start / End Page

  • 891 - 900

PubMed ID

  • 22381424

Pubmed Central ID

  • 22381424

Electronic International Standard Serial Number (EISSN)

  • 1558-3597

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2011.09.075


  • eng

Conference Location

  • United States